PNC-27 research: quick summary
PNC-27 is a chimeric peptide combining a p53 fragment with a membrane-penetrating sequence, studied in cancer cell-biology research models. This Canadian product listing concerns laboratory research material only. It is not an authorized medicine, is not a cancer treatment, does not provide dosing or administration instructions, and is not intended for human or veterinary use.
PNC-27 Canada: PNC-27 10mg Research Product
PNC-27 Canada researchers can order PNC-27 10mg directly from Red Leaf Research Labs. This listing supplies a single 10mg vial of lyophilized PNC-27 for qualified laboratory use, with published analytical information, Canadian-dollar pricing and domestic express fulfilment.
PNC-27 is an in-vitro research tool. It appears in published cell-biology literature and it is supplied here for that purpose and no other.
Red Leaf Research Labs supplies research material to qualified purchasers in Canada. Nothing on this page describes a therapy, a treatment or a permitted personal use. PNC-27 is not a cancer treatment and must not be represented as one.
An Important Note Before the Specifications
PNC-27 is studied in cancer cell models, and that fact attracts searches from people facing a cancer diagnosis. This page is written on the assumption that some of its readers are in that position.
There is no clinical evidence that PNC-27 treats cancer in humans. The published work is in cell culture and animal models. No regulator anywhere has authorized it for any human use, and no legitimate supplier will tell you otherwise. If you or someone close to you is facing a cancer diagnosis, an oncologist is the person to speak to — not a research chemical supplier, and not a forum.
Red Leaf Research Labs supplies this compound to qualified laboratories. It will not advise on any other use, and it will not sell on the basis of one.
PNC-27 10mg Research Format
| Attribute | Detail |
|---|
| Research format | PNC-27 10mg, single vial |
| Physical state | Lyophilized powder |
| Analytical documentation | Third-party report available for the current lot |
| Fulfilment | Domestic Canadian express shipping |
| Intended use | Qualified in-vitro laboratory research only |
PNC-27 Research Specifications
- Compound name: PNC-27
- Class: Chimeric synthetic peptide
- Construction: A fragment of the p53 protein spanning the HDM-2 binding region, fused to a membrane-residency / penetrating sequence
- Research target: HDM-2 (the human homologue of MDM-2) presented in the cell membrane
- Reported mechanism in published work: Selective membrane-pore formation in cells displaying membrane HDM-2, leading to lysis
- Physical format: Lyophilized powder
- Available research quantity: 10mg
- Identity note: Because PNC-27 is a chimeric construct rather than a catalogued natural peptide, confirm the exact sequence on the certificate of analysis rather than relying on the name alone.
- Intended use: Qualified laboratory research only
What Is PNC-27?
PNC-27 is a designed peptide rather than a natural one. It joins two functional parts: a segment of the p53 tumour-suppressor protein corresponding to the region that binds HDM-2, and a membrane-penetrating sequence that carries the construct to and into cell membranes.
The research premise, developed principally by a group at New York Medical College and collaborators, is that some cancer cell lines display HDM-2 in the plasma membrane whereas non-transformed cells largely do not. Published work reports that PNC-27 binds membrane HDM-2 and induces pore formation and lysis in cells that display it, with the selectivity attributed to that difference in membrane presentation.
This is an active and contested area of cell biology. The mechanism has been described in peer-reviewed literature including PNAS, and it remains a laboratory finding in laboratory systems.
What the Literature Does and Does Not Establish
The published record on PNC-27 is in cell culture and animal models, concentrated in a relatively small number of research groups. That concentration is a normal feature of an early-stage research programme and is not in itself a criticism, but a laboratory planning work should know it: independent replication across many groups is limited.
What the record does not contain is human clinical evidence. There are no completed controlled trials establishing efficacy or safety in people, no regulatory authorization in any jurisdiction, and therefore no basis on which any conclusion about human use could be drawn. Findings are protocol-specific and describe behaviour in defined systems.
Why Buy PNC-27 10mg in Canada from a Domestic Research Supplier?
For a chimeric construct, provenance is the point. The name PNC-27 does not fully specify the molecule, so the value of a supplier who publishes verifiable analytical documentation is higher here than for a compound with a settled definition.
Membrane-active peptides are also prone to aggregation, which transit conditions can worsen. Shorter domestic transit reduces that exposure, and a Canadian counterparty gives you recourse when a lot does not match its paperwork.
How This PNC-27 Canada Page Improves on Typical Competitor Listings
- It states plainly that PNC-27 is not a cancer treatment, which is the single most important thing a listing for this compound can do.
- The construct is explained. A p53 fragment fused to a membrane-penetrating sequence — not “a peptide that targets cancer cells”.
- Sequence verification is flagged. A chimeric peptide is defined by its sequence, not its trade name.
- The evidence base is described honestly, including the limited breadth of independent replication.
- No outcome claims. This listing does not describe experiences, results or benefits.
How to Evaluate a PNC-27 Certificate of Analysis
PNC-27 is a designed construct, not a catalogued natural peptide. That makes the sequence — not the name — the thing the report has to establish.
- Full sequence: stated explicitly. A report that says only “PNC-27” has identified a label, not a molecule.
- Construct confirmation: both the p53-derived region and the membrane-penetrating segment accounted for.
- Series distinction: confirm it is PNC-27 and not a neighbouring PNC-series peptide.
- Mass confirmation: consistent with the stated sequence.
- Lot reference and date: cross-check both against the vial.
- Reported quantity: should reconcile with the 10mg format.
- Independent check: a verification reference you can put to the issuing laboratory.
Red Leaf publishes Janoshik reports with a verification key. For chimeric peptides the trade name is a convention, and conventions vary between suppliers — the sequence does not.
PNC-27 10mg Lyophilized Research Format
The 10mg vial arrives as a lyophilized cake. Lyophilization describes the drying process; it is not a purity claim.
PNC-27 carries a membrane-penetrating segment, and amphipathic peptides of this kind are prone to self-association in solution. Preparation route affects what you actually have in the tube: concentration, solvent and mixing method all matter more here than for a simple hydrophilic peptide, and a preparation that looks clear is not necessarily monomeric. Inspect the cake, connect the vial to its report, and follow validated institutional procedures. Background on diluent choice is in bacteriostatic water uses and handling.
Working out concentration for this vial? Our peptide reconstitution calculator converts vial size and bacteriostatic water volume into mg per mL and U-100 syringe units.
How to Buy PNC-27 in Canada for Qualified Research
- Establish eligibility. Confirm the purchaser and institution are authorized to hold research-use material for in-vitro work.
- Get the sequence in writing before ordering. For a chimeric construct this is the order step that matters most.
- Plan for aggregation. Membrane-active peptides need a considered preparation route, not a default one.
- Confirm the destination can receive and store the vial.
- Log it in. Lot reference, arrival condition, storage location, against the study plan.
Fulfilment is to qualified Canadian purchasers by domestic express. Red Leaf supplies material and documentation; it does not advise on study design and provides nothing that supports use in humans or animals.
PNC-27 10mg Canada Procurement Checklist
| Check | What to confirm |
|---|
| Purpose | Authorized in-vitro laboratory research with an approved study plan |
| Identity | Full sequence stated on the report, not the trade name alone |
| Quantity | PNC-27 10mg research format |
| Documentation | Current lot reference, test date, measured amount and purity result |
| Verification | Report can be checked against the issuing laboratory |
| Preparation | Aggregation behaviour accounted for in solution preparation |
| Handling | Storage procedures validated by the receiving institution |
Explore PNC-27 Research Information
For supplier-selection criteria in the Canadian market, review how to evaluate a Canadian research peptide supplier. For the warning signs that separate a documented supplier from a reseller, see identifying irresponsible peptide suppliers in Canada.
PNC-27 research FAQ
Is PNC-27 a cancer treatment?
No. It is an in-vitro research compound. There is no human clinical evidence of efficacy or safety and no regulatory authorization in any jurisdiction for any human use.
What is PNC-27 made of?
A fragment of the p53 protein spanning the HDM-2 binding region, fused to a membrane-penetrating sequence that carries the construct into cell membranes.
What is the reported mechanism?
Published work reports binding to HDM-2 presented in the plasma membrane, followed by selective pore formation and lysis in cells that display it. This has been described in cell-culture and animal models.
Why does the sequence need confirming?
Because PNC-27 is a designed chimeric construct rather than a catalogued natural peptide, the name alone does not define the molecule. The certificate of analysis should state the sequence.
Does Red Leaf Research Labs provide dosing information?
No. Red Leaf Research Labs supplies research material and analytical documentation only.
Research use only. PNC-27 supplied by Red Leaf Research Labs is intended for qualified in-vitro laboratory research. It is not a medicine, not a cancer treatment, not for human or veterinary use, and not for diagnostic or therapeutic application.
Owned and operated by a cf veteran 
